The employee said his stunt backfired after his viral video. Source: TikTok/showmelovejete
RADNOR, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Canaan Inc. (“Canaan”) (NASDAQ: CAN). Canaan is a bitcoin mining hardware manufacturer based in Hangzhou, China. On April 12, 2021, before the market opened, Canaan issued a press release disclosing its fourth quarter 2020 and fiscal year 2020 financial results for the period ended December 31, 2020. Canaan generated $5.9 million in revenue in the fourth quarter and $68.6 million for full-year 2020. Canaan’s fourth quarter 2020 sales had declined more than 93% year-over-year compared to its fourth-quarter fiscal year 2019. Following this news, Canaan’s stock price fell approximately 29.6%, down from its April 9, 2021 closing price of $18.67 to an April 12, 2021 close of $13.14. If you are a Canaan investor and would like to learn more about our investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com; or please visit the following link to fill out our online form http://www.ktmc.com/canaan-inc-investigation?utm_source=PR&utm_medium=Link&utm_campaign=canaan. Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit www.ktmc.com. CONTACT: Kessler Topaz Meltzer & Check, LLPJames Maro, Jr., Esq.Adrienne Bell, Esq.280 King of Prussia RoadRadnor, PA 19087(844) 887-9500info@ktmc.com
Nonprofits Insurance Alliance (NIA) today announced that the board of directors of Nonprofits Insurance Alliance of California (NIAC), an insurer under the NIA brand, has approved a $3 million dividend for policyholders (members). Since 2007, NIAC has cumulatively returned $50 million in dividends to its members, all of whom are 501(c)(3) nonprofits.
Japan Investment Corp (JIC) and Norinchukin Bank are considering buying Toshiba Corp, the Nikkan Kogyo Shimbun reported on Thursday, a Japan-led bid which may be more palatable to regulators and management than rival offers by foreign funds. Private equity fund CVC Capital Partners, which has already made a preliminary offer for Toshiba, may join the bid to take the conglomerate private, but the Japanese funds would lead the offer, the newspaper said. JIC declined to comment when contacted by Reuters, whereas Norinchukin officials were not immediately available.
Timeline was the "star" of Microsoft's big 2018 update for Windows 10 and while it will still remember everything you did, it just won't save that information to the cloud anymore.
A 23-year-old woman left a devastating note in her bedroom for her parents before she took her own life.
TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- COIN Hodl Inc. (TSXV: COIN) (“COIN” or the “Company”) announces that in connection with the Company’s proposed reverse takeover transaction (the “Transaction”) with Tokens.com Inc., the shares of COIN will be delisted from the TSX Venture Exchange (the “Exchange”) at the close of business on or after April 23, 2021 (the “Delisting”) subject to receipt of all necessary approvals. The exact delisting date will be confirmed in a subsequent press release. Further Information Completion of the Transaction is subject to a number of conditions, and, if applicable, disinterested shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of COIN should be considered highly speculative. The Exchange has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this press release. For further information, please contact: COIN Hodl Inc.Ben CubittChief Executive OfficerTelephone: (416) 479-5407Email: ir@coinhodlinc.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact are forward-looking statements, and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often using phrases such as “expects”, “anticipates”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends”, or variations of such words and phrases, or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved, are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the timing of the proposed Delisting. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include: general business, economic, competitive, political and social uncertainties; delay or failure to receive any necessary board, shareholder or regulatory approvals; that factors may occur which impede or prevent Tokens’ future business plans; and other factors beyond the control of COIN and Tokens. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. The terms and conditions of the Transaction may change based on the receipt of tax, corporate and securities law advice for each of the parties. Except as required by law, COIN and Tokens assume no obligation to update the forward-looking statements, whether they change as a result of new information, future events or otherwise, except as required by law.
Japan Investment Corp (JIC) and Norinchukin Bank are considering buying Toshiba Corp, the Nikkan Kogyo Shimbun reported on Thursday, a Japan-led bid which may be more palatable to regulators and management than rival offers by foreign funds. Private equity fund CVC Capital Partners, which has already made a preliminary offer for Toshiba, may join the bid to take the conglomerate private, but the Japanese funds would lead the offer, the newspaper said. JIC declined to comment when contacted by Reuters, whereas Norinchukin officials were not immediately available.
RPM earnings call for the period ending March 31, 2021.
CAG earnings call for the period ending March 31, 2021.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ebang International Holdings, Inc. (NASDAQ: EBON), 3D Systems Corporation (NYSE: DDD), Amdocs Limited (NASDAQ: DOX), and FibroGen, Inc. (NASDAQ: FGEN). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Ebang International Holdings, Inc. (NASDAQ: EBON) Class Period: June 26, 2020 and April 5, 2021 Lead Plaintiff Deadline: June 7, 2021 On April 6, 2021, Hindenburg Research published a report alleging, among other things, that Ebang is directing proceeds from its IPO last year into a “series of opaque deals with insiders and questionable counterparties.” According to the report, Ebang raised $21 million in November 2020, claiming the proceeds would go “primarily for development,” and that instead the funds were directed to repay related-party loans to a relative of the Ebang’s Chief Executive Officer, Dong Hu. The report also noted that Ebang’s earlier efforts to go public on the Hong Kong Stock Exchange had failed due to widespread media coverage of a sales inflation scheme with Yindou, a Chinese peer-to-peer online lending platform that defrauded 20,000 retail investors in 2018, with $655 million “vanish[ing] into thin air.” On this news, the Company’s share price fell $0.82, or approximately 13%, to close at $5.53 per share on April 6, 2021. On April 6, 2021, after the market closed, Ebang issued a statement stating that, though it believed the report “contain[ed] many errors, unsupported speculations and inaccurate interpretations of events,” the “Board, together with its Audit Committee, intends to further review and examine the allegations and misinformation therein and will take whatever necessary and appropriate actions may be required to protect the interest of its shareholders.” On this news, the Company’s share price fell $0.12, or 2.17%, to close at $5.41 per share on April 7, 2021. The stock price continued to decline over the next trading session by $0.38, or 7%, to close at $5.03 per share on April 8, 2021. The complaint, filed on April 8, 2021, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the proceeds from Ebang’s public offerings had been directed to an low yield, long term bonds to an underwriter and to related parties rather than used to develop the Company’s operations; (2) that Ebang’s sales were declining and the Company had inflated reported sales, including through the sale of defective units; (3) that Ebang’s attempts to go public in Hong Kong had failed due to allegations of embezzling investor funds and inflated sales figures; (4) that Ebang’s purported cryptocurrency exchange was merely the purchase of an out-of-the-box crypto exchange; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. For more information on the Ebang class action go to: https://bespc.com/cases/EBON 3D Systems Corporation (NYSE: DDD) Class Period: May 6, 2020 to March 1, 2021 Lead Plaintiff Deadline: June 8, 2021 On March 2, 2021, 3D Systems filed a NT-10-K with the SEC, stating that their 10- K filing would be delayed. On this news, 3D Systems’s stock price fell $7.62 per share, or more than 19.6%, from closing at $38.79 per share on March 1, 2021 to close at $31.17 per share on March 2, 2021, damaging investors. The complaint, filed on May 9, 2021, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) 3D Systems lacked proper internal controls over financial reporting; and (2) as a result, 3D Systems’ public statements were materially false and/or misleading at all relevant times. For more information on the 3D Systems class action go to: https://bespc.com/cases/DDD Amdocs Limited (NASDAQ: DOX) Class Period: December 13, 2016 to March 30, 2021 Lead Plaintiff Deadline: June 8, 2021 Amdocs, through its global subsidiaries, provides software and services to communications, cable and satellite, entertainment, and media industry service providers worldwide. Historically, the Company’s largest percentage of revenues come from its North American business, mostly the U.S., particularly from large customers including, among others, AT&T Inc. (“AT&T”). On March 31, 2021, Jehoshaphat Research (“Jehoshaphat”) published a short-seller report addressing Amdocs, which alleged that Amdocs overstated its profits, evidenced by steady parent profits despite declining subsidiary profits; that there was a concerning pattern of reputable auditors resigning, only to be replaced by “scandal-plagued or tiny shops”; that Amdocs “window-dressed” its balance sheets to keep its large borrowing a secret, namely by paying down its debt just prior to the end of each quarter, therefore showing a debt-free balance sheet on that day, before reborrowing the money shortly thereafter; and that all of the foregoing was corroborated by former employees and direct competitors of the Company, who noted that Amdocs was losing AT&T as a customer, as well as a former American Amdocs executive, who stated that the Company’s “US business was declining at a rate of [around] 7% annually . . . but then we would see the company [publish results that] say North America is stable.” On this news, Amdocs’ ordinary share price fell $9.19 per share, or 11.58%, to close at $70.15 per share on March 31, 2021. The complaint, filed on April 9, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs’ reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. For more information on the Amdocs class action go to: https://bespc.com/cases/DOX FibroGen, Inc. (NASDAQ: FGEN) Class Period: November 8, 2019 to April 6, 2021 Lead Plaintiff Deadline: June 11, 2021 On August 18, 2019, the Company issued a press release announcing, “Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results” and that shortly thereafter on December 23, 2019, FibroGen announced that it had submitted a New Drug Application to the Food and Drug Administration for roxadustat. On April 6, 2021, the Company revealed that its previously disclosed safety data included undisclosed post-hoc changes to the stratification factors and did not include analyses based on the pre-specified stratification factors. As a result of these changes, FibroGen was forced to concede that roxadustat, contrary to prior representations, did not reduce the risk of cardiovascular events or hospitalization as compared to a currently approved anemia injection used as a control based on pre-specified stratification factors. On this news, the Company’s share price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021. The complaint, filed on April 12, 2021, alleges that defendants failed to disclose to investors: (i) that the Company’s prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of CKD included post-hoc changes to the stratification factors; (ii) that FibroGen’s analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) that, based on these analyses, the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) that, as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) that, as a result of the foregoing, defendants’ statements about the Company's business, operations and prospects were materially misleading and/or lacked a reasonable basis. For more information on the FibroGen class action go to: https://bespc.com/cases/FGEN About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
Denmark’s fragmented executive search market highlights strong performance from Boyden, with leading MedTech expert Søren Rysholt Christiansen joining as Partner Partner Søren Rysholt Christiansen COPENHAGEN, Denmark, April 15, 2021 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to announce strong growth in Denmark in 2020 despite the impact of Covid-19 and welcomes MedTech expert Søren Rysholt Christiansen as Partner in Boyden’s global healthcare & life sciences practice. Morten Winther, Managing Partner, Boyden Denmark, comments, “The pandemic has created a fragmented market with contraction among larger executive search firms, while Boyden has benefited from working at the most senior levels and collaborating with regional and global colleagues. In addition, our dual office structure in Denmark differentiates our firm, underlines our commitment to the market and puts us near our clients. We have been rewarded with a stronger financial performance than last year, increasing our turnover by 25%, and we are poised to deliver exceptional results this year.” Boyden Denmark’s gross profit increased by approx. 40% in 2020, with a result before tax of DKK 5.8 million with the same number of employees. Boyden Denmark has proved its capabilities with significant traction across industries, particularly in renewable energy. During the pandemic, almost solely online, Boyden won and completed the search for a new CEO for wind market leader Gurit AG. In just 16 weeks, Boyden Denmark mapped the global leadership talent in the industry, collaborating with Boyden’s teams in Switzerland, Spain and the Benelux region, two leading wind energy markets, presented final candidates to the nomination committee and helped finalize the appointment of Mitja Schulz as CEO. “During a year when everyone has suffered from Covid-19, our dual offices setup in Denmark and a broad customer and industry coverage demonstrates the robustness of our business model,” added Henrik Harbo, Managing Partner, Boyden Denmark. “This has enabled us to grow our business among different industries and client demographics such as privately-held companies and private equity investors that value our ability to deliver the right leadership aligned to their growth agendas.” The appointment of Søren Rysholt Christiansen completes Boyden’s sector coverage, providing executive search, board consulting, and CEO succession to clients in industrial, consumer & retail, and financial services. Being a MedTech expert, Christiansen further strengthens Boyden’s mature global healthcare & life sciences practice, and brings exceptional local expertise to clients in Denmark and the Nordic region. Christiansen has a distinguished career as CEO at MedTech pioneer Acarix AB - a spin-out from Coloplast A/S - and has held other leadership positions at dentistry supplier XO CARE A/S, hearing aid producer GN Hearing, medical equipment supplier BK Medical/BK Ultrasound, and medical device leaders Elos Medtech and COOK Medical. He was a member of the Public Affairs Focus Group with European medical device industry association Eucomed, and board member of the Danish medical device association Medicoindustrien. Culturally fluent, Christiansen has commercial experience in EMEA, the United States, Asia, and Latin America. He holds an executive MBA and a Graduate Diploma in International Business from Copenhagen Business School. “I am delighted to be appointed Partner with Boyden Denmark and to support MedTech, Biotech, and Pharma clients, who are substantial contributors to the Danish economy,” commented Søren Rysholt Christiansen, Partner, Boyden Denmark. “Healthcare and life science is growing in importance as a key industry for Denmark. My appointment underlines the critical role that business leaders, and leadership experts play in supporting export earnings and economic growth in Denmark. I have walked in the shoes of Boyden’s clients and have led businesses with different ownership structures, so I feel well-placed to contribute to the growth of Boyden’s business in the region and worldwide.” About Boyden Working out of our 75 offices in over 45 countries, our global reach enables us to serve client needs anywhere they conduct business. We connect great companies with great leaders through executive search, interim management, and leadership consulting solutions. Boyden is ranked in the top 10 on Forbes’ America’s Best Executive Recruiting Firms for the past four years. For further information, visit www.boyden.com. Contacts: Chris Swee, BoydenGlobal Head of MarketingT: +1 914 747 0172E: cswee@boyden.comHenrik Harbo, BoydenManaging Partner, DenmarkT: +45 29 709 759E: hharbo@boyden.comMorten Winther, BoydenManaging Partner, DenmarkT: +45 202 82884E: mwinther@boyden.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dfaff2e9-749e-4d66-a72c-a2baf6e02c19
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Canaan, Inc. (NASDAQ: CAN) on behalf of Canaan stockholders. Our investigation concerns whether Canaan has violated the federal securities laws and/or engaged in other unlawful business practices.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against AdaptHealth, Inc. (NASDAQ: AHCO) on behalf of AdaptHealth stockholders. Our investigation concerns whether AdaptHealth has violated the federal securities laws and/or engaged in other unlawful business practices.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Porch Group, Inc. (NASDAQ: PRCH) on behalf of Porch Group stockholders. Our investigation concerns whether Porch Group has violated the federal securities laws and/or engaged in other unlawful business practices.
It means Harry will not have to face being one of the only close family members who is not in uniform at the service
YouTube star-turned-pro-boxer Jake Paul previews his April 17 bout vs. Ben Askren and opens up on his dark period over the last few years saying fame isn't all it's cracked up to be.
Tech giant has teamed up with University of Washington and Seattle Flu Study for project
Securing justice for young man’s family a priority, Mike Elliott tells Andrew Buncombe
Johnson & Johnson's COVID-19 vaccine remains in limbo in the United States as a health panel calls for more data before making a decision on how and whether to resume use of the one-dose shot.The US Centers for Disease Control and Prevention (CDC) advisory panel on Wednesday delayed a vote on how best to use the J&J; shot even after a US Food and Drug Administration scientist told advisers he believed warnings could mitigate the risk of extremely rare but serious blood clots.
Hi Josh is back for another season to tell us what they're really saying on Married at First Sight.
Yahoo Finance